April 29, 2020 / 6:44 AM / a month ago

BRIEF-Pharma Mar Signs Agreement With Immedica Pharma AB For Distribution And Marketing Of Anti-Tumor Drug Lurbinectedin

April 29 (Reuters) - Pharma Mar SA:

* SIGNED AGREEMENT WITH IMMEDICA PHARMA AB FOR EXCLUSIVE DISTRIBUTION AND MARKETING, IF APPROVED, OF ANTI-TUMOR DRUG LURBINECTEDIN

* WILL RECEIVE AN UPFRONT PAYMENT OF EUR 2 MILLION

* AGREEMENT FOR DISTRIBUTION IN UK, IRELAND, NORDIC COUNTRIES, SOME COUNTRIES WITHIN EASTERN EUROPE, MIDDLE EAST AND NORTH AFRICA

* WILL ALSO BE ELIGIBLE FOR ADDITIONAL REGULATORY MILESTONE PAYMENTS

* WILL RECEIVE 50% OF FUTURE SALES IN EUROPE AND 40% OF FUTURE SALES IN THE MIDDLE EAST

* WILL RETAIN EXCLUSIVE PRODUCTION RIGHTS FOR PRODUCT, WHICH WILL BE SUPPLIED TO IMMEDICA FOR COMMERCIAL AND CLINICAL USE

* WILL RETAIN THE RIGHTS TO DISTRIBUTE AND MARKET THE PRODUCT IN REST OF EUROPE Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below